Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. September 2025 16:03 ET | Quelle: SciSparc Ltd

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
25. September 2025 07:05 ET | Quelle: SciSparc Ltd

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
28. August 2025 09:24 ET | Quelle: SciSparc Ltd

SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc

TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
28. August 2025 06:45 ET | Quelle: SciSparc Ltd

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
07. August 2025 07:32 ET | Quelle: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
30. Juli 2025 16:34 ET | Quelle: SciSparc Ltd

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
30. Juli 2025 08:12 ET | Quelle: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
22. Juli 2025 07:32 ET | Quelle: SciSparc Ltd

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to...
24. Juni 2025 17:03 ET | Quelle: SciSparc Ltd

SciSparc Announces 1-for-21 Reverse Share Split

Tel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of...
27. Mai 2025 07:32 ET | Quelle: SciSparc Ltd

SciSparc Announces Publication of Japanese Patent Application

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...

Vorherige Seite

Nächste Seite